All In Biotech

NDA 022572 · Glaukos

Mitosol

Mitomycin · Topical

Priority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Apr 23, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Feb 7, 2012

Approved uses

1

Original approval plus efficacy supplements

Registered trials

286

89 Phase 3, 41 recruiting

FAERS reports

2,564

2,416 serious, 377 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 23, 2025.

Mitosol ® is an antimetabolite indicated for use as an adjunct to ab externo glaucoma surgery. Mitosol ® is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. ( 1 )

Mechanism: Mitosol ® inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. Cellular RNA and protein synthesis may also be suppressed.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • MITOSOL · MITOMYCIN 0.2MG/VIAL · FOR SOLUTION, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mitomycin" as an intervention, any sponsor and status, largest first.

All 286 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use364
  • diarrhoea152
  • nausea132
  • thrombocytopenia107
  • neutropenia106
  • drug ineffective101
  • disease progression98
  • pancytopenia93
  • vomiting89
  • fatigue78
  • death76
  • leukopenia74

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200467
200577
200686
200796
2008125
200979
201094
2011137
2012134
2013129
201495
2015115
201698
201787
2018127
2019160
2020152
2021126
202289
202374
2024133
2025177
2026107

Recalls

1 FDA enforcement reports for this application.

  • Jan 3, 2013 · Class I · Terminated

    Non-Sterility: one or more components of the kit have been found to be contaminated with yeast.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,194 on PubMed

Sponsor: Glaukos

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.